Lapatinib (Tyverb®): Re-analysis of data on use following treatment with trastuzumab
2019.04.30
Active substance: lapatinib
The European Medicines Agency (EMA) is updating the prescribing information for Tyverb® (lapatinib) after irregularities had been observed in results of a study involving postmenopausal women.
To the risk information full text (available in German only)